Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Quentin30on Apr 11, 2024 12:03pm
90 Views
Post# 35983489

RE:RE:RE:RE:RE:RE:AACR 2024 : Cancer vaccines get reintroduction with pathway

RE:RE:RE:RE:RE:RE:AACR 2024 : Cancer vaccines get reintroduction with pathway News they know nothing about.. LOL... come on wazzak, you can do better than that.

I attend Type C meetings as part of my role...  chump... So I think I'd have a clue as to timelines, and what is going on...

ONCY probably doesn't have a confirmed biomarker yet... or one assessed by FDA. Being able to separate non-responders from (potential) responders up front has always been hoped to minimise the number of patients required for recruitment (and thus trial duration). I guess they must just about have enough patient OS data, to make them think they have a shot at getting their biomarker confirmed by FDA.

BUT the outcome is an an UNKNOWN... IF ONCY was absolutely certain their biomarker would be accepted, the trial design would already be in the bag... 

This isn't a done dea and it is neither negative or positive until FDA feeds back to ONCY at the end of June. If you don't think it's important to assess the potential pitfalls of an investment before you count your winnings... then maybe this explains why you're only up 2 pennies on your ONCY investment over the past year.

I'm neither negative nor positive about this news... It depends what happens in June.

<< Previous
Bullboard Posts
Next >>